Health and Fitness Health and Fitness
Wed, January 5, 2011
[ Wed, Jan 05th 2011 ] - Market Wire
LabCorp is Scheduled to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
LifePoint Hospitals to Participate in 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Almirall and Forest Announce Positive Results fro .. of Aclidinium Bromide and the Phase IIb Studies w
[ Wed, Jan 05th 2011 ] - Market Wire
AngioDynamics Reports Fiscal 2011 Second Quarter Financial Results
[ Wed, Jan 05th 2011 ] - Market Wire
Alkermesa? Corporate Presentation to be Webcast at the JPMorgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Celgene ofrece nuevos datos sobre presentaciones normativas
[ Wed, Jan 05th 2011 ] - Market Wire
Celgene komt met update over het indienen van reglementaire aanvragen
[ Wed, Jan 05th 2011 ] - Market Wire
NeuroMetrix Announces New Strategic Direction
[ Wed, Jan 05th 2011 ] - Market Wire
Thermo Fisher Scientific to Present at the 29th A .. PMorgan Healthcare Conference on January 11, 2011
[ Wed, Jan 05th 2011 ] - Market Wire
InSite Vision Completes Patient Enrollment in ISV .. Study for Post-Surgical Ocular Pain and Swelling
[ Wed, Jan 05th 2011 ] - Market Wire
MannKind to Present at the JP Morgan 29th Annual HealthcareConference
[ Wed, Jan 05th 2011 ] - Market Wire
Kinetic Concepts, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Medisafe 1 Technologies Issues Letter to Shareholders
[ Wed, Jan 05th 2011 ] - Market Wire
PerkinElmer to Present at 29th Annual JP Morgan Healthcare Conference
[ Wed, Jan 05th 2011 ] - Market Wire
Teva Completes Acquisition of Th©ramex
Tue, January 4, 2011
[ Tue, Jan 04th 2011 ] - Market Wire
Law Office of Brodsky & Smith, LLC Announces Investigation of CPEX Pharmaceuticals, Inc.
[ Tue, Jan 04th 2011 ] - Market Wire
Finkelstein Thompson LLP Announces Investigation of CPEX Pharmaceuticals, Inc.
[ Tue, Jan 04th 2011 ] - Market Wire
Merck to Hold Fourth-Quarter 2010 Sales and Earnings Conference Call on Feb. 3
[ Tue, Jan 04th 2011 ] - Market Wire
The Law Office of Robbins Umeda LLP Announces an .. ion of CPEX Pharmaceuticals, Inc. by FCB I Holdin
[ Tue, Jan 04th 2011 ] - Market Wire
St. Jude Medical to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Tue, Jan 04th 2011 ] - Market Wire
The Law Firm of Levi & Korsinsky, LLP Launches an .. Breaches of Fiduciary Duty by the Board of CPEX P
[ Tue, Jan 04th 2011 ] - Market Wire
Briscoe Law Firm Investigates CPEX Pharmaceutical .. ders Concerning the Acquisition by Footstar, Inc.
[ Tue, Jan 04th 2011 ] - Market Wire
Illumina to Present at J.P. Morgan Healthcare Conference
[ Tue, Jan 04th 2011 ] - Market Wire
BioCryst to Present at J.P. Morgan Healthcare Conference
[ Tue, Jan 04th 2011 ] - Market Wire
Kiadis Pharma Signs License Agreement with Hospira to Commercialize ATIRa" in Europe and Asia
[ Tue, Jan 04th 2011 ] - Market Wire
Bio-Path Holdings to Present at the Biotech Showcasea" 2011 Conference
[ Tue, Jan 04th 2011 ] - Market Wire
ZIOPHARM Oncology Appoints Mark Thornton, M.D., P .. tive Vice President and Chief Development Officer
[ Tue, Jan 04th 2011 ] - Market Wire
AVEO Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
[ Tue, Jan 04th 2011 ] - Market Wire
Pro-Pharmaceuticals to Present Corporate Update at San Francisco Biotech Conference
[ Tue, Jan 04th 2011 ] - Market Wire
Celgene fornisce aggiornamenti su domande sottoposte ad autorit regolamentatrici

Celgene fornisce aggiornamenti su domande sottoposte ad autorit regolamentatrici


Published on 2011-01-04 10:00:33 - Market Wire
  Print publication without navigation


BOUDRY, Svizzera--([ BUSINESS WIRE ])--Celgene International Srl (NASDAQ: CELG) ha annunciato la presentazione di richieste agli organi regolamentatori per le sue terapie per i tumori ematici, REVLIMID (lenalidomide) e ISTODAX (romidepsin).

La societ ha presentato una domanda per l'autorizzazione alla commercializzazione (MAA) per l'approvazione del REVLIMID (lenalidomide) per il trattamento di mantenimento di pazienti affetti da mieloma multiplo di recente diagnosi che non abbiano mostrato miglioramenti dopo un trattamento iniziale a base di melfalan, prednisone e REVLIMID, o in seguito al trapianto autologo di cellule staminali.

Il testo originale del presente annuncio, redatto nella lingua di partenza, la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodit del lettore e devono rinviare al testo in lingua originale, che l'unico giuridicamente valido.

Contributing Sources